Evidence map›Paper›PMID 27385913›Full record

ArticleBreast cancer : basic and clinical research2015

Increasing Tumor Accessibility with Conjugatable Disulfide-Bridged Tumor-Penetrating Peptides for Cancer Diagnosis and Treatment.

Venkata Ramana Kotamraju, Shweta Sharma, Poornima Kolhar, Lilach Agemy, James Pavlovich, Erkki Ruoslahti

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer : basic and clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment.Journal of controlled release : official journal of the Controlled Release Society · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Venkata Ramana KotamrajuCancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.; Department of Molecular, Cellular, and Developmental Biology, Center for Nanomedicine, University of California, Santa Barbara, Santa Barbara, CA, USA.
Shweta SharmaCancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.
Poornima KolharDepartment of Biomolecular Science and Engineering, University of California, Santa Barbara, Santa Barbara, CA, USA.
Lilach AgemyDepartment of Plant Sciences, Weizmann Institute of Science, Rehovot, Israel.
James PavlovichDepartment of Chemistry and Biochemistry, University of California, Santa Barbara, Santa Barbara, CA, USA.
Erkki RuoslahtiCancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.; Department of Molecular, Cellular, and Developmental Biology, Center for Nanomedicine, University of California, Santa Barbara, Santa Barbara, CA, USA.
Cancer Research Center · USDiscovery Institute · USSanford Burnham Prebys Medical Discovery Institute · USUniversity of California, Santa Barbara · USWeizmann Institute of Science · IL

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael Jackson · 1985 to 2026
$107.2M
Engineering Multifunctional NanoparticlesR01CA124427 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BHATIA, SANGEETA N. · 2006 to 2010
$4.7M
Tumor Penetrating Peptides for Cancer TargetingR01CA152327 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI RUOSLAHTI, ERKKI · 2011 to 2015
$2.0M
NCI NIH HHS P30 CA030199NCI NIH HHS R01 CA124427NCI NIH HHS R01 CA152327
6 · The paper itself

Abstract

Tumor-homing peptides with tissue-penetrating properties increase the efficacy of targeted cancer therapy by delivering an anticancer agent to the tumor interior. LyP-1 (CGNKRTRGC) and iRGD (CRGDKGPDC) are founding members of this class of peptides. The presence of the cysteines forming the cyclizing disulfide bond complicates conjugation of these peptides with other molecules, such as drugs. Here, we report the synthesis of conjugatable disulfide-bridged peptides and their conjugation to biologically important molecules. We have synthesized the LyP-1, iRGD, and CRGDC (GACRGDCLGA) peptides with a cysteine or maleimidohexanoic acid added externally at N-terminus of the sequences. Subsequent conjugation to payloads yielded stable compounds in which the tumor-homing properties of the peptide and the biological activity of the payload were retained.

Indexed as

conjugatable disulfide peptidescyclic peptide conjugation nanoworm conjugateshoming peptidesoligonucleotide conjugatestumor-penetrating peptidestumor targeting

Identifiers

PMID27385913
PMCPMC4924884
OpenAlexW2468059078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.